These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1492 related articles for article (PubMed ID: 22410028)

  • 1. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma downstaging in liver transplantation.
    Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
    Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.
    Kim PT; Onaca N; Chinnakotla S; Davis GL; Jennings LW; McKenna GJ; Ruiz RM; Levy MF; Goldstein R; Klintmalm GB
    Clin Transplant; 2013; 27(2):311-8. PubMed ID: 23351129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?
    Chan AC; Chan SC; Chok KS; Cheung TT; Chiu DW; Poon RT; Fan ST; Lo CM
    Liver Transpl; 2013 Apr; 19(4):411-9. PubMed ID: 23447460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival.
    Bharat A; Brown DB; Crippin JS; Gould JE; Lowell JA; Shenoy S; Desai NM; Chapman WC
    J Am Coll Surg; 2006 Oct; 203(4):411-20. PubMed ID: 17000383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma.
    Choi HJ; Kim DG; Na GH; Hong TH; You YK
    Transplant Proc; 2012 Mar; 44(2):399-402. PubMed ID: 22410027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria.
    Takuma Y; Nouso K; Makino Y; Gotoh T; Toshikuni N; Morimoto Y; Shimomura H; Yamamoto H
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1417-24. PubMed ID: 21884248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results.
    Di Sandro S; Giacomoni A; Slim A; Lauterio A; Mangoni I; Mihaylov P; Pirotta V; Aseni P; De Carlis L
    Hepatogastroenterology; 2012; 59(114):505-10. PubMed ID: 22353516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival.
    Moon JI; Kwon CH; Joh JW; Choi GS; Jung GO; Kim JM; Shin M; Choi SJ; Kim SJ; Lee SK
    Transplant Proc; 2012 Mar; 44(2):487-93. PubMed ID: 22410053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Necrosis percentage of radiologically treated hepatocellular carcinoma at hepatectomy for liver transplantation.
    Rossetto A; Adani GL; Baccarani U; Bresadola V; Lorenzin D; Sponza M; Vit A; De Anna D; Bresadola F
    Transplant Proc; 2011 May; 43(4):1095-7. PubMed ID: 21620061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
    Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.